Tumor growth promoting activity of an immunosuppressive substance and its modulation by protein-bound polysaccharide PSK. 1987

M Fujii, and T Fujii, and K Saito, and N Takahashi, and C Yoshikumi, and J Kakuchi, and Y Kawai
Biomedical Research Laboratories, Kureha Chemical Industry Co., Tokyo, Japan.

The role of an immunosuppressive substance (IS), which is increased in the serum of tumor-bearing animals, was examined in rats. IS isolated from cancerous ascites fluid of rats was administered to Walker 256 tumor-bearing rats to examine changes in the serum level of IS, tumor growth and survival rate. PSK, an immunomodulator, was also administered. Serum IS increased with tumor growth. The administration of IS to tumor-transplanted rats caused the tumor to grow and shortened the animals' survival time. The administration of PSK, however, inhibited the increase in serum level of IS, resulting in the suppression of tumor growth and a prolongation of survival time. The findings suggested that IS is a useful parameter for predicting not only tumor growth but also the therapeutic effect of immunomodulators such as PSK.

UI MeSH Term Description Entries
D007122 Immunoelectrophoresis A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D002279 Carcinoma 256, Walker A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed) Carcinosarcoma 256, Walker,Walker Carcinoma 256,Walker Carcinosarcoma 256
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M Fujii, and T Fujii, and K Saito, and N Takahashi, and C Yoshikumi, and J Kakuchi, and Y Kawai
January 1991, Anticancer research,
M Fujii, and T Fujii, and K Saito, and N Takahashi, and C Yoshikumi, and J Kakuchi, and Y Kawai
January 1988, International journal of immunopharmacology,
M Fujii, and T Fujii, and K Saito, and N Takahashi, and C Yoshikumi, and J Kakuchi, and Y Kawai
January 2000, Clinical & experimental metastasis,
M Fujii, and T Fujii, and K Saito, and N Takahashi, and C Yoshikumi, and J Kakuchi, and Y Kawai
July 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
M Fujii, and T Fujii, and K Saito, and N Takahashi, and C Yoshikumi, and J Kakuchi, and Y Kawai
November 1998, Immunopharmacology,
M Fujii, and T Fujii, and K Saito, and N Takahashi, and C Yoshikumi, and J Kakuchi, and Y Kawai
January 1988, International journal of immunopharmacology,
M Fujii, and T Fujii, and K Saito, and N Takahashi, and C Yoshikumi, and J Kakuchi, and Y Kawai
January 1985, Biochemical and biophysical research communications,
M Fujii, and T Fujii, and K Saito, and N Takahashi, and C Yoshikumi, and J Kakuchi, and Y Kawai
January 1979, Advances in experimental medicine and biology,
M Fujii, and T Fujii, and K Saito, and N Takahashi, and C Yoshikumi, and J Kakuchi, and Y Kawai
March 2009, Anticancer research,
M Fujii, and T Fujii, and K Saito, and N Takahashi, and C Yoshikumi, and J Kakuchi, and Y Kawai
January 1992, Biotherapy (Dordrecht, Netherlands),
Copied contents to your clipboard!